{"nctId":"NCT00236951","briefTitle":"Intravenous (IV) Iron vs. No Iron as the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy","startDateStruct":{"date":"2003-02"},"conditions":["Anemia"],"count":224,"armGroups":[{"label":"Venofer + erythropoietin (responders)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: iron sucrose injection USP"]},{"label":"erythropoietin only (responders)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: stable erythropoietin therapy"]},{"label":"Venofer+erythropoietin(non-responders)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: iron sucrose injection USP"]},{"label":"erythropoietin only (non-responders)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: stable erythropoietin therapy"]}],"interventions":[{"name":"iron sucrose injection USP","otherNames":[]},{"name":"stable erythropoietin therapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histological Diagnosis of Cancer\n* Hgb \\</= 10\n* Ongoing or Planned Chemotherapy\n* Body Weight \\>50kg\n* Free of Active Infection\n* Karnofsky Status 60% to 100%\n\nExclusion Criteria:\n\n* Active infection\n* Use of Multivitamins with iron within one week of entry\n* Myelophthisic bone marrow involvement by tumor except hematologic malignancy\n* Concurrent medical condition that would prevent compliance or jeopardize the health of the patient\n* Use of any IV iron products within two months of study entry\n* Blood Transfusions\n* Hypoplastic bone marrow failure state\n* Acute Leukemia\n* Myeloproliferative syndrome\n* Uncontrolled hypertension","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to the Maximum Hemoglobin Level During Stage 2 (Week 9 Through Week 21).","description":"The hemoglobin baseline was defined as the average of the last 2 hemoglobin values during stage 1 (through week 8).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"1.59"},{"groupId":"OG001","value":"1.8","spread":"1.39"},{"groupId":"OG002","value":"2.5","spread":"1.88"},{"groupId":"OG003","value":"1.3","spread":"1.73"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":59},"commonTop":["Nausea","Fatigue","Vomiting NOS","Diarrhea NOS","Back pain"]}}}